Literature DB >> 1530994

Morphologic, hemodynamic and coronary perfusion characteristics in severe left ventricular hypertrophy secondary to systemic hypertension and evidence for nonatherosclerotic myocardial ischemia.

J L Houghton1, A A Carr, L M Prisant, W B Rogers, T W von Dohlen, N C Flowers, M J Frank.   

Abstract

Patients with the clinical diagnosis of ischemic heart disease who were found to be free of significant coronary artery atherosclerotic disease (n = 150) underwent coronary vasodilator reserve testing, 2-dimensional echocardiography, and dipyridamole limited-stress thallium testing. After exclusions (predominantly for technically poor coronary artery Doppler signals or suboptimal echocardiography), 100 patients formed the study population. The purpose was to characterize typical cardiac and coronary artery findings in hypertensive patients with severe left ventricular (LV) hypertrophy (n = 15) and to investigate the evidence for myocardial ischemia unrelated to coronary atherosclerosis in early and advanced hypertensive heart disease. Normotensive and hypertensive control groups without LV hypertrophy (n = 12 and 34, respectively) were used for comparison. Severe LV hypertrophy was defined as LV mass index greater than or equal to 50% above established gender specific norms using 2-dimensional-directed M-mode echocardiography and the cube equation corrected to agree with necropsy estimates of mass. Clinical characteristics more often associated with severe LV hypertrophy were black race (67%), diabetes mellitus (33%), proteinuria (47%) and elevated creatinine (1.5 +/- 0.9 mg/dl). Baseline electrocardiograms and dipyridamole limited-stress thallium scans were highly likely to be abnormal (94 and 73%, respectively). Both eccentric and concentric cardiac hypertrophies were found in the severe group. Ejection fraction was significantly lower (0.51 vs 0.68, p = 0.002) and basal coronary flow velocity higher (12.0 vs 5.0 cm/s, p = 0.0004) among these patients when compared with normotensive control patients. Coronary flow reserve did not differ between control groups but was significantly depressed in patients with severe LV hypertrophy (2.5 vs 3.9, p = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530994     DOI: 10.1016/0002-9149(92)91308-q

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  The clinical assessment of coronary flow reserve in patients with coronary artery disease.

Authors:  Michael Ragosta
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

Review 2.  Peroxisome proliferator-activated receptor alpha and hypertensive heart disease.

Authors:  Maria J Goikoetxea; Javier Beaumont; Javier Díez
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death.

Authors:  F H Messerli; F Soria
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

4.  Clinical Factors Associated with Obstructive Coronary Artery Disease in Patients with Out-of-Hospital Cardiac Arrest: Data from the Korean Cardiac Arrest Research Consortium (KoCARC) Registry.

Authors:  Jiesuck Park; Jonghwan Shin; Hack Lyoung Kim; Kyoung Jun Song; Jin Hee Jung; Hui Jai Lee; Kyoung Min You; Woo Hyun Lim; Jae Bin Seo; Sang Hyun Kim; Joo Hee Zo; Myung A Kim
Journal:  J Korean Med Sci       Date:  2019-06-10       Impact factor: 2.153

5.  Mortality in patients with microvascular disease.

Authors:  David S Marks; Surrendra Gudapati; L M Prisant; Brooke Weir; Caroline diDonato-Gonzalez; Jennifer L Waller; Jan L Houghton
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-06       Impact factor: 3.738

6.  Early outgrowth pro-angiogenic cell number and function do not correlate with left ventricular structure and function in conventional hemodialysis patients: a cross-sectional study.

Authors:  James R Lineen; Michael Kuliszewski; Niki Dacouris; Christine Liao; Dmitriy Rudenko; Djeven P Deva; Marc Goldstein; Howard Leong-Poi; Ron Wald; Andrew T Yan; Darren A Yuen
Journal:  Can J Kidney Health Dis       Date:  2015-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.